Our open marketplace gives you the freedom to choose from the world’s leading AI and molecular tests, all integrated into a single, seamless diagnostic operating system.
Molecular Testing
Molecular tests available on our platform for simplified ordering and faster results
CxBladder Triage
Urine Test – Bladder
Reduces unnecessary invasive procedures while identifying patients who truly need follow-up, streamlining care and improving patient comfort and efficiency.
CxBladder Monitor
Urine Test – Bladder
Provides continuous, non-invasive monitoring for bladder cancer recurrence, giving clinicians actionable insights while minimizing repeated invasive testing.
Vesta® Bladder — Valar Labs
Urine Test – Bladder
Identifies patients at risk for bladder cancer using a simple, non-invasive test, supporting timely follow-up and more efficient patient management.
Invitae Renal/Urinary Tract Cancers Panel
Blood Test – Urology
Helps identify hereditary cancer risks so clinicians can proactively manage patient care, guide early screening, and support family risk counseling.
BRACAnalysis & MyRisk Update Test
Blood Test – Prostate
Provides critical insight into inherited cancer risk, empowering clinicians to guide preventive measures, screening, and targeted treatment for patients and relatives.
Caris MI Cancer Seek™
Blood Test – Prostate
Enables early cancer detection across multiple cancer types, helping clinics intervene sooner, improve patient outcomes, and reduce uncertainty in initial diagnostic decisions.
ClevelandDx ISOPSA
Blood Test – Prostate
ClevelandDx’s ISOPSA measures the quality of the PSA signal, not just the quantity, for a smarter approach to detecting high-grade prostate cancer.
ConfirmMDx
Tissue Test – Prostate
Reduces uncertainty in negative prostate biopsies by identifying patients who may have undetected cancer, preventing missed diagnoses and unnecessary repeat procedures.
DecipherBx
Tissue Test – Prostate
Predicts prostate cancer aggressiveness to guide personalized treatment, helping clinicians balance intervention versus surveillance effectively.
Decipher GRID
Tissue Test – Prostate
Seamlessly integrates with existing prostate biopsy orders to deliver additional genomic insights without extra workflow complexity, keeping care coordinated.
Genomic Prostate Score
Tissue Test – Prostate
Supports personalized treatment decisions by predicting prostate cancer aggressiveness, helping avoid overtreatment and guiding the right intervention at the right time.
MyRisk Test
Tissue Test – Prostate
Identifies inherited cancer risk, enabling proactive screening, early intervention, and informed treatment planning for patients and their families.
Prolaris Biopsy Test
Tissue Test – Prostate
Prolaris’ test predicts prostate cancer progression risk, helping clinicians make confident, personalized treatment decisions and reduce over treatment.
Precise Tumor
Tissue Test – Prostate
Guides individualized treatment strategies by predicting tumor behavior and therapy response, helping clinicians tailor care and improve patient outcomes.
KnowError
Other
Ensures sample integrity and patient identity, preventing misdiagnoses or inaccurate biomarker results, and safeguarding clinical decision-making.
Artificial Intelligence Partners
AI algorithms available on our platform
Acu-URO17
Bladder AI on Urine
Provides a highly sensitive biomarker to “rule out” bladder cancer with 99% certainty, helping patients avoid unnecessary invasive cystoscopies.
AIxURO
Bladder AI on Urine
Uses computational cytology to accurately identify suspicious or atypical cells in non-invasive urine samples.
PANProfiler Colorectal
GI Tissue AI
Delivers rapid, accurate molecular biomarker results (e.g., MSI/MMR status) directly from routine pathology images in minutes instead of days or weeks.
PaigeAI
Prostate AI
Acts as a clinical-grade “second set of eyes” to detect subtle cancerous foci that pathologists might miss on a slide.
Artera AI Prostate Test
Prostate AI
Predicts long-term outcomes and identifies which patients will specifically benefit from hormone therapy (ADT) to avoid over-treatment.
AiryDx
Prostate AI
Enhances risk stratification by automatically identifying aggressive morphological features like cribriform patterns and perineural invasion.
DeepDx Prostate
Prostate AI
Automates the quantification of Gleason patterns and tumor length in seconds to ensure fast, consistent grading across entire labs.
PaigeAI
Prostate AI
Acts as a clinical-grade “second set of eyes” to detect subtle cancerous foci that pathologists might miss on a slide.
Verily Gleason Grading Algorithm
Prostate AI
Reduces human subjectivity by providing “expert-level” subspecialist grading to community pathologists to ensure diagnostic accuracy.
Cleo Skin
Derm AI
Accelerates dermatopathology workflows by automatically detecting and measuring biomarkers for melanoma and other major skin cancers
Scanners
Lumea is scanner agnostic, with integrations spanning over 75 scanners across 25 different makes and models.
The vendors below are among our preferred partners.
“Everyone talks about collaboration, but Lumea clearly has it embedded in its DNA. It’s incredibly exciting to see this ethos attract such a diverse, driven, and capable group, each looking not to outdo the other but to bring their strengths to the arena and push for a better future.”
Dr. John Salmon, MDSalmon Upstream, LLC
Request Information
Contact us now for more information about how comprehensive digital pathology can benefit your practice
